Abstract: Ovarian cancer, especially for advanced ovarian cancer, is a kind of common gynecologic malignant tumor with higher rate of relapse and death. It is the main reason that bulk unremovable tumor after cytoreductive surgery result in multidrug resistance, relapse and bad prognosis. It has been testified for nearly thirty years that neoadjuvant chemotherapy could reduce tumor volume, improve optimal cytoreduction rate and prognosis. However improved optimal cytoreduction rate failed to prolong the median lifetime. Therefore, we should evaluate objectively for the efficacy of neoadjuvant chemotherapy in advanced ovarian cancer based on the clinical meta-analysis.

Key words: Ovarian cancer, Neoadjuvant, Chemotherapy